KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET.
A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentation.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827892054/en/
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
[email protected]
Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
[email protected]
KEYWORDS: Massachusetts Europe United States United Kingdom North America
INDUSTRY KEYWORDS: Health Infectious Diseases General Health Research Science Pharmaceutical Biotechnology
MEDIA:
| Logo |
 |